+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

P

Actively Recruiting

This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.

Age: 18Years - 68YearsAll GendersPhase 2
79 locations
O

Actively Recruiting

Researchers are evaluating patient characteristics, treatment patterns, and both short- and long-term outcomes in people with symptomatic obstructive hypertrophic cardiomyopathy HCM in the United States and Europe. The study focuses on patients receiving mavacamten, other treatments, or no treatment due to intolerance or previous treatment failure. The US sub-study particularly assesses mavacamtens safety, while the European sub-study evaluates both the safety and effectiveness of mavacamten in real-world settings. Participants receive treatment as prescribed by their physicians according to standard care for symptomatic obstructive HCM. One group takes mavacamten, while another receives beta-blockers, non-dihydropyridine calcium channel blockers, andor disopyramide. Some participants may be untreated due to intolerance or treatment failure. Treatments follow routine clinical care without study-driven changes. Throughout the study, participants are monitored for heart function changes, including heart failure events and left ventricular outflow tract gradients, over periods up to five years. Researchers collect data on arrhythmias, hospitalizations, mortality, and quality of life using questionnaires and biomarker tests. This observational registry captures real-world experiences to better understand treatment outcomes and patient health over time.

Age: 18Years +All Genders
101 locations
A

Actively Recruiting

Researchers are evaluating AP301, a novel iron-based phosphate binder, in patients with chronic kidney disease who are receiving maintenance dialysis and have elevated blood phosphate levels. This phase 3, randomized, double-blind study aims to determine whether AP301 lowers blood phosphate and how it affects serum calcium, calcium times phosphate, and intact parathyroid hormone levels. The trial also assesses any discomfort or medical problems during treatment and its impact on quality of life in Chinese patients. Participants will first stop all phosphate-lowering medications. They will then take either AP301 or a low-dose comparator considered ineffective three times daily for 8 weeks. Following this, all participants receive AP301 three times daily for 24 weeks, with dose adjustments based on blood phosphate levels and physician judgment. Finally, participants will take either AP301 or the comparator three times daily for 3 weeks. Additional treatments may be given if blood phosphate levels become too high or low. During the study, participants will undergo regular assessments including blood tests to monitor serum phosphate, calcium, and parathyroid hormone levels. Electrocardiogram tests will measure changes in QT intervals. Safety is monitored by tracking adverse events throughout the trial, which lasts up to 37 weeks. The primary outcome is the change in serum phosphate concentration from baseline to the end of week 8, with ongoing evaluations over the entire study period.

Age: 12Years +All GendersPhase 3
42 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
P

Actively Recruiting

Researchers are evaluating DMX-200 repagermanium, a drug that blocks a receptor involved in inflammation, in patients with focal segmental glomerulosclerosis FSGS who are also receiving an angiotensin II receptor blocker ARB. This Phase 3 study aims to assess the safety and effectiveness of DMX-200 compared to placebo over two years in adults and adolescents aged 12 to 17 years. The study is led by Dimerix Bioscience Pty Ltd and includes a double-blind period followed by an open-label extension to observe long-term effects. Participants receive either 120 mg of DMX-200 or a matching placebo capsule twice daily for 104 weeks during the double-blind treatment phase. Afterward, those who complete this phase may enter a two-year open-label extension where all participants receive DMX-200 twice daily. The study includes a screening and qualification period lasting 6 to 14 weeks, a possible titration phase, a stabilization phase, and a follow-up period after treatments. Throughout the trial, patients will undergo assessments including urine proteincreatinine ratio and kidney function tests like estimated glomerular filtration rate eGFR at multiple time points up to week 104 and during the extension. Safety and tolerability are closely monitored through regular evaluations, adverse event tracking, and follow-up visits. Total participation may last about 230 weeks, covering all study phases and follow-up periods.

Age: 12Years - 80YearsAll GendersPhase 3
220 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
E

Actively Recruiting

Researchers are evaluating how well LY3537021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy in adults with cancer. This phase 2 study compares LY3537021 with a placebo, both given along with standard anti-nausea medicines. The study focuses on adults who have not previously received chemotherapy and are planned to receive specific types of chemotherapy drugs. Participants receive either LY3537021 or placebo as a subcutaneous injection before chemotherapy, along with standard antiemetic treatments taken by mouth, intravenously, or through skin patches, depending on local guidelines. The chemotherapy drugs used include cisplatin or anthracycline with cyclophosphamide administered intravenously. The study uses a double-blind and randomized design to compare the two groups. Throughout the study, participants are monitored for nausea and vomiting during the period from the start of chemotherapy through 120 hours after the first infusion. Researchers assess the proportion of participants who have a complete response, meaning no vomiting and no need for additional rescue medication, particularly in the delayed phase. Participants remain in the study for about two months until all parts are completed, including safety evaluations and pharmacokinetic measurements.

Age: 18Years +All GendersPhase 2
67 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.

Age: 18Years - 75YearsAll GendersPhase 3
330 locations
R

Actively Recruiting

Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.

Age: 12Years +All GendersPhase 3
316 locations

1-10 of 30

1